AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing multiple ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

AstraZeneca’s chief executive has discussed shifting the company’s stock market listing to the US in a move that would deal a huge blow to London.

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting a shift of the company’s primary stock listing from the London to the U.S.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times reported on Tuesday, citing multiple sources. Soriot has privately expressed a ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing multiple sources.